Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ
Smiles: C=CC(=O)NC1=CC2=C(NC3=CC(Cl)=C(F)C=C3)N=CN=C2C=C1OCCCN1CCOCC1
Formula: C23H26N4O5S
BRL52537 inhibited neuronal apoptosis and brain damage
PubMed PMID: 10900073
(R)-SLV 319 703 100 μM) enhances nuclear TAZKi: 7. 8 and 7943 nM for CB1 and CB2 receptors, respectively by SLV 319 (R) SLV 319 is a CB1 receptor antagonist. Central cannabinoid (CB1) receptor antagonists can be used in the treatment of various diseases including cognitive disorders, neuroinflammatory disorders, obesity, septic shock, psychosis, addiction, as well as gastrointestinal disorders. In vitro: (R) SLV 319 is the inactive enantiomer of SLV 319 with 100 fold less affinity for the CB1
US$ 24412.50
US$ 5718.96
US$ 9444.75
US$ 9444.75
US$ 9444.75
US$ 9738.75
US$ 9917.25
US$ 31145.62
US$ 9738.75
US$ 8872.50